Cibus (CBUS) Non-Current Deffered Revenue (2016 - 2018)
Cibus (CBUS) posted Non-Current Deffered Revenue of $91000.0 for Q3 2018, down 21.55% sequentially from $116000.0 in Q2 2018, and down 79.32% YoY from $440000.0 in Q3 2017.
Cibus (CBUS) Non-Current Deffered Revenue (2016 - 2018) Analysis & Trends
Cibus has reported Non-Current Deffered Revenue for 3 years, with the latest figure at $91000.0 in Q3 2018.
- Quarterly Non-Current Deffered Revenue fell 79.32% year-over-year to $91000.0 in Q3 2018, while the trailing twelve-month figure through Sep 2018 was $91000.0 (down 79.32% YoY) and the FY2017 annual result came in at $289000.0, down 54.77% from the prior year.
- Non-Current Deffered Revenue retreated to $91000.0 in Q3 2018 per CBUS's latest filing, from $116000.0 in the prior quarter.
- Over five years, Non-Current Deffered Revenue peaked at $639000.0 in Q4 2016 and troughed at $91000.0 in Q3 2018.
- A 3-year average of $329428.6 and a median of $289000.0 in 2017 frame the typical range for Non-Current Deffered Revenue.
- The sharpest annual moves came in 2017 and 2018: Non-Current Deffered Revenue sank 54.77% in 2017, then sank 79.32% in 2018.
- Over 3 years, Non-Current Deffered Revenue stood at $639000.0 in 2016, then tumbled by 54.77% to $289000.0 in 2017, then slumped by 68.51% to $91000.0 in 2018.
- According to Business Quant data, Non-Current Deffered Revenue over the past three periods registered $91000.0, $116000.0, and $278000.0 for Q3 2018, Q2 2018, and Q1 2018 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 220.40 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 147.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Cibus | 129.72 Mn | 109.29 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2018 | 91,000.00 |
| Jun 30, 2018 | 116,000.00 |
| Mar 31, 2018 | 278,000.00 |
| Dec 31, 2017 | 289,000.00 |
| Sep 30, 2017 | 440,000.00 |
| Jun 30, 2017 | 453,000.00 |
| Dec 31, 2016 | 639,000.00 |